EphB4 is a membrane-bound
receptor tyrosine kinase (RTK) commonly over-produced by many epithelial
cancers but with low to no expression in most normal adult tissues. EphB4 over-production promotes
ligand-independent signaling pathways that increase
cancer cell viability and stimulate migration and invasion. Several studies have shown that normal
ligand-dependent signaling is tumour suppressive and therefore novel
therapeutics which block the tumour promoting
ligand-independent signaling and/or stimulate tumour suppressive
ligand-dependent signaling will find application in the treatment of
cancer. An EphB4-specific polyclonal antibody, targeting a region of 200
amino acids in the extracellular portion of EphB4, showed potent in vitro anti-
cancer effects measured by an increase in apoptosis and a decrease in anchorage independent growth.
Peptide exclusion was used to identify the
epitope targeted by this antibody within the
cysteine-rich region of the
EphB4 protein, a sequence defined as a potential
ligand interacting interface. Addition of antibody to
cancer cells resulted in phosphorylation and subsequent degradation of the
EphB4 protein, suggesting a mechanism that is
ligand mimetic and tumour suppressive. A
monoclonal antibody which specifically targets this identified extracellular
epitope of EphB4 significantly reduced
breast cancer xenograft growth in vivo confirming that EphB4 is a useful target for
ligand-mimicking antibody-based anti-
cancer therapies.